{"id":35673,"date":"2023-12-21T20:43:26","date_gmt":"2023-12-21T20:43:26","guid":{"rendered":"https:\/\/hereforthegirls.org\/?p=35673"},"modified":"2023-11-27T20:45:11","modified_gmt":"2023-11-27T20:45:11","slug":"breast-cancer-news-of-note-advances-in-breast-cancer-research-highlighted-at-esmo-2023","status":"publish","type":"post","link":"https:\/\/hereforthegirls.org\/breast-cancer-news-of-note-advances-in-breast-cancer-research-highlighted-at-esmo-2023\/","title":{"rendered":"Breast Cancer News of Note: Advances in Breast Cancer Research Highlighted at ESMO 2023"},"content":{"rendered":"\n

<\/p>\n\n\n\n

Disclaimer statement: The information and resources contained within this document are for educational purposes only. Please make sure to discuss any resources with the Here for the Girls Team. This information should not be used for self-diagnosis or treatment. This information should not be used in lieu of care from a licensed physician or mental health practitioner. Although the content of the resources has been reviewed by the Here for the Girls Team, you should use caution whenever accessing or referring to information from outside sources, including the Internet.<\/em><\/p>\n\n\n\n

The European Society for Medical Oncology (ESMO) Congress 2023 met in Spain to shed light on new research surrounding breast cancer research. BreastCancer <\/em>highlighted the main takeaways presented this year. A clinical trial called TROPION-Breast01 focused on metastatic breast cancer and used Dato-DXd as a therapy medicine (2023). The results of the trial indicate that the therapy medicine showed promise and stated the following<\/p>\n\n\n\n

\u201c[the therapy medicine] offered longer progression-free survival than standard chemotherapy for inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy.\u201d (2023)<\/p>\n\n\n\n

An additional finding is related to Verzenio, a medication used to stop cancer cell growth (Cleveland Clinic, 2023). Verzenio was studied in the monarchE study that has spanned five years with over 5,000 participants (DePolo, 2023). The results indicated the following, \u201c[participants] were less likely to have a breast cancer recurrence in the breast area\u2026[and] less likely to have a distant, or metastatic, recurrence\u201d (2023). Additionally, statistics reported that participants who took Verzenio and hormonal therapy were \u201c32% less likely to have a recurrence\u2026[and] 32.5% less likely to have a distant, or metastatic, recurrence.\u201d (DePolo, 2023) The main takeaway from the monarchE study is related to the benefits of Verzenion for individuals with \u201cearly-stage, hormone receptor-positive, HER2-negative breast cancer with a high risk of reccurence,\u201d (2023).<\/p>\n\n\n\n

Research related to pregnancy and breast cancer treatments was also presented. Studies showed that pregnancy following breast cancer treatment is safe for pregnant patients and their child. Researchers advised patients to still know of potential risks related to treatments and recurrence that may impact becoming pregnant. It\u2019s recommended for patients to consult with their physicians if they are planning to become pregnant. The following are additional resources related to pregnancy and breast cancer:<\/p>\n\n\n\n